Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 7/20 | 0.76 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.76 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852209 | 1.00 | SLC1A3 (0.76) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL1953602 | 1.00 | SLC1A3 (0.76) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| Water SCHEMBL30419716 | 0.98 | SLC1A3 (0.73) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL28285770 | 0.91 | SLC1A2 (0.65) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL21873930 | 0.88 | SLC1A2 (0.67) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL2596995 | 0.88 | SLC1A2 (0.67) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL2597203 | 0.88 | SLC1A2 (0.67) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL2004120 | 0.88 | SLC1A2 (0.67) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL2004125 | 0.88 | SLC1A2 (0.67) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL2819524 | 0.87 | SLC1A2 (1.00) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112839715-B | Process for producing compound for inhibiting SHP2 activity | 诺华股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-12138262-B2 | Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition | NOVARTIS AG (CH) | 2024-11-12 | — | — | US | disclosed |
| EP-4282416-A2 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-20210346375-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| EP-3856345-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2021-08-04 | — | — | EP | disclosed |
| CN-112839715-A | Method for preparing active compound for inhibiting SHP2 | 诺华股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| WO-2020065453-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-04-02 | — | — | WO | disclosed |
| US-20160168138-A1 | PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT | REDDY S LAB LIMTED DR (IN) | 2016-06-16 | — | — | US | disclosed |
| US-20150252039-A1 | Process For The Preparation Of Pyrido[2,1-a] Isoquinoline Derivatives By Catalytic Asymmetric Hydrogenation Of An Enamine | HOFFMANN-LA ROCHE INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150126743-A1 | Process For The Preparation Of Pyrido [2,1-A] Isoquinoline Derivatives Comprising Optical Resolution Of An Enamine | HOFFMANN-LA ROCHE INC. | 2015-05-07 | — | — | US | disclosed |
| US-20080076925-A1 | PROCESS FOR THE PREPARATION OF PYRIDO [ 2-1-A] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | US | disclosed |
| WO-2008031749-A1 | PROCESS FOR THE PREPARATION OF PYRIDO[2,1-A]ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| US-20080071087-A1 | PROCESS FOR THE PREPARATION OF PYRIDO [2,1-a] ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE | HOFFMAN-LA ROCHE INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008031750-A2 | PROCESS FOR THE PREPARATION OF PYRIDO[2,1-A]ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007124329-A1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
| US-7271173-B2 | Mixed kappa/mu opioids and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20040259901-A1 | Mixed kappa/mu opioids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-23 | — | — | US | disclosed |
| WO-2004045562-A2 | MIXED KAPPA/MU OPIOIDS AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003029183-A1 | METHOD OF SYNTHESISING CHICORIC ACID | UNIVERSITE DE BORDEAUX I (FR) | 2003-04-10 | — | — | WO | disclosed |
| US-6100401-A | Process for preparing the d-threo isomer of methylphenidate hydrochloride | NOVARTRIS AG (CH) | 2000-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076925-A1 | PROCESS FOR THE PREPARATION OF PYRIDO [ 2-1-A] ISOQUINOLINE DERIVATIVES BY CATALYTIC ASYMMETRIC HYDROGENATION OF AN ENAMINE | PNISR, SFPQ, PLPBP | SLC1A3 4323/4885SLC1A2 3395/4885SLC1A1 4422/4885 |
| US-20040259901-A1 | Mixed kappa/mu opioids and uses thereof | OPRK1, OPRD1, OPRL1 | SLC1A3 438/4885SLC1A2 405/4885SLC1A1 213/4885 |
| US-12138262-B2 | Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition | PTPN5, PTPN7, PTPN1 | SLC1A3 4458/4885SLC1A2 4627/4885SLC1A1 4620/4885 |
| US-20160168138-A1 | PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT | KMO, HCRTR2, COMT | SLC1A3 495/4885SLC1A2 630/4885SLC1A1 848/4885 |
| US-20210346375-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION | PTPN5, PTPN7, PTPN1 | SLC1A3 4458/4885SLC1A2 4627/4885SLC1A1 4620/4885 |
| US-20150252039-A1 | Process For The Preparation Of Pyrido[2,1-a] Isoquinoline Derivatives By Catalytic Asymmetric Hydrogenation Of An Enamine | IDO2, IDO1, H1-2 | SLC1A3 3622/4885SLC1A2 2350/4885SLC1A1 3716/4885 |
| US-20150126743-A1 | Process For The Preparation Of Pyrido [2,1-A] Isoquinoline Derivatives Comprising Optical Resolution Of An Enamine | PNPO, ENO1, CHRM1 | SLC1A3 3228/4885SLC1A2 1554/4885SLC1A1 2579/4885 |
| US-20080071087-A1 | PROCESS FOR THE PREPARATION OF PYRIDO [2,1-a] ISOQUINOLINE DERIVATIVES COMPRISING OPTICAL RESOLUTION OF AN ENAMINE | PNPO, ENO1, CHRM1 | SLC1A3 3228/4885SLC1A2 1554/4885SLC1A1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.